Neoadjuvant SNF Precision Therapy Phase III

Launched by FUDAN UNIVERSITY · Mar 30, 2025

Keywords

ClinConnect Summary

The Neoadjuvant SNF Precision Therapy Phase III clinical trial is studying a new treatment approach for women with early-stage or locally advanced breast cancer that is hormone receptor-positive (HR+) and HER2-negative. This trial aims to compare the effectiveness and safety of a specific type of chemotherapy, tailored based on a classification called SNF, with or without additional precision medicine agents. The goal is to see if this personalized treatment can help these women before they undergo surgery to remove the cancer.

To be eligible for this trial, participants must be females aged 18 to 70 who have been diagnosed with HR+/HER2- breast cancer and meet certain health criteria. They should have a good performance status, meaning they can carry out daily activities without significant issues. Participants will need to agree to have surgery after the treatment if their condition allows for it. The trial is not yet recruiting participants, but those who join can expect close monitoring and support throughout the treatment process. It's also important to know that women who can become pregnant will need to use contraception during the study and for a period after treatment.

Gender

FEMALE

Eligibility criteria

• Eligibility Criteria:
• • 1. Female patients aged 18 to 70 years.
• • 2. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• • 3. Histologically confirmed HR-positive/HER2-negative breast cancer (defined as: (1) ER-positive: ≥10% tumor cells positive by immunohistochemistry (IHC).
• • (2) PR-positive: ≥10% tumor cells positive by IHC. (3) HR-positive: ER and/or PR positive. (4) HER2-negative: HER2 0-1+ by IHC or HER2 2+ with negative FISH (no amplification).
• • 4. Confirmed SNF2/3/4 subtype based on H\&E staining combined with digital pathology molecular subtyping.
• • 5. Clinical tumor stage: cT1c-T2, cN1-N2 or cT3-T4, cN0-N2. 6. Agreement to undergo breast cancer surgery if meeting the criteria for resection after neoadjuvant therapy.
• • 7. Adequate organ function, meeting the following criteria: Hemoglobin (Hb) ≥90 g/L; Absolute neutrophil count (ANC) ≥1.5×10⁹/L; Platelet count (PLT) ≥75×10⁹/L; Total bilirubin (TBIL) ≤1.5×ULN (upper limit of normal); Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤3×ULN; Serum creatinine (Cr) ≤1×ULN; Creatinine clearance rate (CrCl) \>50 mL/min (calculated by Cockcroft-Gault formula).
• • 8. Baseline left ventricular ejection fraction (LVEF) ≥55% measured by echocardiography or MUGA scan.
• • 9. Negative serum pregnancy test for women of childbearing potential. Contraception requirement: Women of childbearing potential must use medically approved contraception during treatment and for at least 3 months after the last dose of the study drug.
• • 10Voluntary participation with signed informed consent, good compliance, and willingness to follow up.
• Exclusion Criteria:
• • 1. Stage IV (metastatic) breast cancer.
• • 2. History of invasive breast cancer.
• • 3. History of ductal carcinoma in situ (DCIS) or lobular carcinoma in situ (LCIS).
• • 4. Prior systemic therapy for breast cancer (chemotherapy, endocrine therapy, or anti-HER2 therapy), or prior excisional biopsy/radiotherapy of primary breast tumor and/or axillary lymph nodes (excluding diagnostic biopsy for primary breast cancer or surgery for benign breast tumors).
• • 5. Other malignancies within the past 5 years (except cured cervical carcinoma in situ or non-melanoma skin cancer).
• • 6. Participation in any other investigational drug study within 4 weeks prior to randomization.
• • 7. Peripheral neuropathy ≥ Grade 2 (per NCI-CTCAE v5.0).
• 8. Severe cardiovascular or cerebrovascular diseases within 6 months prior to randomization, including but not limited to:
• • Congestive heart failure,
• • Unstable angina,
• • Severe uncontrolled arrhythmias,
• • Clinically significant valvular disease,
• • Uncontrolled severe hypertension,
• • Myocardial infarction, or
• • Cerebrovascular accident.
• • 9. Any severe uncontrolled systemic disease that may interfere with the treatment plan, including significant cardiovascular, pulmonary, or metabolic disorders.
• • 10. Major surgery within 4 weeks prior to randomization without full recovery, or anticipated need for major surgery during the study treatment.
• • 11. Systemic corticosteroid use (\>10 mg prednisone equivalent daily) or other immunosuppressants within 2 weeks prior to the first dose of study drug (except for prophylactic anti-allergy or antiemetic purposes).
• • \* Inhaled/topical steroids or physiologic steroid replacement doses (≤10 mg/day prednisone equivalent) are permitted in the absence of active autoimmune disease.
• • 12. Administration of anti-cancer vaccines or live vaccines within 4 weeks prior to the first dose of study drug.
• 13. Active autoimmune disease or history of autoimmune disorders (e.g., interstitial lung disease, colitis, hepatitis, hypophysitis, vasculitis, nephritis, hyper/hypothyroidism), EXCEPT:
• • Vitiligo,
• • Childhood asthma/allergies resolved without intervention in adulthood,
• • Stable hypothyroidism on hormone replacement,
• • Type 1 diabetes on stable insulin therapy.
• • Exclusion: Asthma requiring bronchodilators.
• • 14. Immunodeficiency (e.g., HIV-positive, congenital/acquired immune deficiency) or history of organ/allogeneic bone marrow transplantation.
• • 15. History of interstitial lung disease (except radiation pneumonitis without steroid treatment) or non-infectious pneumonitis.
• 16. Active liver disease, including:
• • Hepatitis B (HBsAg-positive with HBV-DNA ≥1000 IU/mL),
• • Hepatitis C (HCV-Ab-positive with detectable HCV-RNA), or
• • Autoimmune hepatitis.
• • 17. Pregnancy or lactation.
• • 18. Known hypersensitivity to the study drug(s), its excipients, or severe allergic reactions to monoclonal antibodies.
• • 19. History of substance abuse, alcoholism, or drug addiction.
• • 20. Uncontrolled psychiatric/neurological disorders (e.g., epilepsy, dementia) or poor compliance.
• • 21. Any other condition that may increase study risk, interfere with treatment/outcomes, or render the patient unsuitable for participation per investigator's judgment.